Clinical Trials Register

Trials with a EudraCT protocol (378)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

378 result(s) found for: Squamous cell lung carcinoma. Displaying page 1 of 19.

EudraCT Number: 2021-004189-37

Sponsor Protocol Number: HCQHNLcancer

Start Date*: 2022-03-09

Sponsor Name:OSPEDALE SAN RAFFAELE

Full Title: Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer

Medical condition: Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx), or Resectable Non-small cell lung cancer (NSCLC, only Lung Squamous Cell Carci...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10078181	Laryngeal squamous cell carcinoma stage 0	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10030964	Oral carcinoma	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10037352	Pulmonary carcinoma stage 0	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025123	Lung squamous cell carcinoma stage II	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025122	Lung squamous cell carcinoma stage I	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-004003-31

Sponsor Protocol Number: SQUINT-FoRT04

Start Date*: 2017-03-22

Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)

Full Title: SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, phase II trial of Nivolumab plus Ipilimumab versus platinum-based chemotherapy in chemonaive metastatic or rec...

Medical condition: Patients with Stage IIIB-not amenable to radical treatment or Stage IV metastatic or recurrent squamous-cell lung carcinoma (SqLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041826	Squamous cell carcinoma of lung	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2017-002474-39

Sponsor Protocol Number: VBN-01

Start Date*: 2018-01-17

Sponsor Name:Nykode Therapeutics AS

Full Title: An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy...

Medical condition: Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10027481	Metastatic melanoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029514	Non-small cell lung cancer NOS	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10038409	Renal cell carcinoma NOS	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077840	Urothelial cancer of renal pelvis	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041823	Squamous cell carcinoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2014-003356-30

Sponsor Protocol Number: M18-007

Start Date*: 2014-12-09

Sponsor Name:OncoMed Pharmaceuticals, Inc.

Full Title: A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo versus Carboplatin, Pemetrexed plus 1 or 2 Truncated Courses of Demcizumab in Subjects with Non-Squamous Non-Sm...

Medical condition: Non-Squamous Non-Small Cell Lung Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed) BE (Completed) IT (Prematurely Ended) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2011-004792-36

Sponsor Protocol Number: CA209-017

Start Date*: 2012-09-11

Sponsor Name:Bristol-Myers Squibb International Corporation

Full Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Revised Protocol N...

Medical condition: Squamous cell Non-small cell lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Completed) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) ES (Ongoing) AT (Completed) HU (Completed) CZ (Completed) NO (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2016-001352-21

Sponsor Protocol Number: ABT-C5-2016

Start Date*: 2016-09-19

Sponsor Name:Ability Pharmaceuticals, SL

Full Title: A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC

Medical condition: Squamous Cell Non-Small Cell Lung Cancer and advanced endometrial cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014743	Endometrial carcinoma	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025120	Lung squamous cell carcinoma recurrent	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071533	Lung squamous cell carcinoma metastatic	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014747	Endometrial carcinoma recurrent	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025124	Lung squamous cell carcinoma stage III	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014745	Endometrial carcinoma metastatic	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014749	Endometrial carcinoma stage II	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014751	Endometrial carcinoma stage IV	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025125	Lung squamous cell carcinoma stage IV	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014750	Endometrial carcinoma stage III	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025126	Lung squamous cell carcinoma stage unspecified	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: (No results available)

EudraCT Number: 2015-003715-38

Sponsor Protocol Number: D4190C00006

Start Date*: 2016-05-12

Sponsor Name:MedImmune LLC

Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer

Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029520	Non-small cell lung cancer stage IIIA	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066490	Progression of non-small cell lung cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2012-003201-96

Sponsor Protocol Number: I4X-MC-JFCK

Start Date*: 2013-03-13

Sponsor Name:Eli Lilly and Company

Full Title: A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Ce...

Medical condition: Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2013-001985-41

Sponsor Protocol Number: 09-09

Start Date*: 2013-08-27

Sponsor Name:Onconova Therapeutics Inc.

Full Title: A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

Medical condition: Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041823	Squamous cell carcinoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Prematurely Ended)

Trial results: View results

EudraCT Number: 2016-003030-24

Sponsor Protocol Number: EDEN-GOIRC-04-2016

Start Date*: 2017-05-24

Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)

Full Title: “An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-l...

Medical condition: Advanced stage (IIIB/IV) squamous non-small cell lung cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025124	Lung squamous cell carcinoma stage III	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025125	Lung squamous cell carcinoma stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2019-004194-95

Sponsor Protocol Number: CC-90011-ST-002

Start Date*: 2020-04-09

Sponsor Name:Celgene Corporation

Full Title: A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers.

Medical condition: Small cell lung cancer (SCLC) and squamous non-small cell lung cancer (sqNSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10041071	Small cell lung cancer stage unspecified	LLT
	21.1	100000004864	10029514	Non-small cell lung cancer NOS	LLT
	21.1	100000004864	10025126	Lung squamous cell carcinoma stage unspecified	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2009-012607-26

Sponsor Protocol Number: MIMEB

Start Date*: 2009-12-10

Sponsor Name:University of Cologne

Full Title: MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Adv...

Medical condition: Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC), first-line.

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.0		10025054	Lung cancer non-small cell stage IIIB	LLT
	12.0		10025055	Lung cancer non-small cell stage IV	LLT
	12.0		10029515	Non-small cell lung cancer recurrent	PT
	12.0		10029521	Non-small cell lung cancer stage IIIB	PT
	12.0		10029522	Non-small cell lung cancer stage IV	PT
	12.0		10029521	Non-small cell lung cancer stage IIIB	LLT
	12.0		10029522	Non-small cell lung cancer stage IV	LLT
	12.0		10050017	Lung cancer metastatic	LLT
	12.0		10059515	Non-small cell lung cancer metastatic	LLT
	12.0		10061873	Non-small cell lung cancer	LLT
	12.0		10066490	Progression of non-small cell lung cancer	LLT
	12.0		10050017	Lung cancer metastatic	PT
	12.0		10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2014-002604-25

Sponsor Protocol Number: CA184-153

Start Date*: 2014-10-22

Sponsor Name:Bristol-Myers Squibb International Corporation

Full Title: Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subj...

Medical condition: LUNG CANCER (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.1	100000004864	10025044	Lung cancer	LLT
	17.1	100000004864	10029514	Non-small cell lung cancer NOS	LLT
	17.1	100000004864	10041071	Small cell lung cancer stage unspecified	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) DE (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2012-005541-21

Sponsor Protocol Number: CBKM120D2204

Start Date*: 2013-06-20

Sponsor Name:NOVARTIS FARMA

Full Title: A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-s...

Medical condition: squamous non small cell lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001254	Adenosquamous cell lung cancer stage IV	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001253	Adenosquamous cell lung cancer stage IIIB	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) CZ (Completed) BE (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2022-000339-21

Sponsor Protocol Number: JK08.1.01

Start Date*: 2022-08-29

Sponsor Name:Salubris Biotherapeutics, Inc.

Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ...

Medical condition: Unresectable Locally Advanced or Metastatic Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10041067	Small cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10053571	Melanoma	LLT
	24.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10085663	Clear cell papillary renal cell carcinoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10077840	Urothelial cancer of renal pelvis	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10067821	Head and neck cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10075566	Triple negative breast cancer	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10030137	Oesophageal adenocarcinoma	PT
	25.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061534	Oesophageal squamous cell carcinoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10040810	Skin carcinoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10051971	Pancreatic adenocarcinoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073071	Hepatocellular carcinoma	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008229	Cervical cancer	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014720	Endometrial adenocarcinoma	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066474	Thyroid cancer	PT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10083238	Luminal breast cancer	LLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061451	Colorectal cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10071114	Metastatic gastric adenocarcinoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Trial now transitioned) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2012-002392-33

Sponsor Protocol Number: N12HYB

Start Date*: 2012-06-12

Sponsor Name:NKI-AVL

Full Title: Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cm

Medical condition: NSCLC stage III or inoperable stage II

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062041	Lung infiltration malignant	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023779	Large cell lung cancer stage III	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025036	Lung adenocarcinoma stage II	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10062042	Lung neoplasm	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029520	Non-small cell lung cancer stage IIIA	PT
	14.1	10038738 - Respiratory, thoracic and mediastinal disorders	10025082	Lung disorder	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025031	Lung adenocarcinoma	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025069	Lung carcinoma cell type unspecified stage III	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001250	Adenosquamous cell lung cancer stage II	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025124	Lung squamous cell carcinoma stage III	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025123	Lung squamous cell carcinoma stage II	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029518	Non-small cell lung cancer stage II	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025037	Lung adenocarcinoma stage III	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2011-000711-85

Sponsor Protocol Number: MEF4984g

Start Date*: 2011-10-17

Sponsor Name:Genentech, Inc

Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB IN PATIENTS ...

Medical condition: ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025054	Lung cancer non-small cell stage IIIB	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025052	Lung cancer non-small cell stage III	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025048	Lung cancer non-small cell recurrent	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025051	Lung cancer non-small cell stage II	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025046	Lung cancer cell type unspecified stage IV	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025055	Lung cancer non-small cell stage IV	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025053	Lung cancer non-small cell stage IIIA	LLT
	14.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025050	Lung cancer non-small cell stage I	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended)

Trial results: View results

EudraCT Number: 2014-005614-29

Sponsor Protocol Number: CC-486-NSCL-001

Start Date*: 2015-11-19

Sponsor Name:Celgene Corporation

Full Title: A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembroliz...

Medical condition: Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066490	Progression of non-small cell lung cancer	LLT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029515	Non-small cell lung cancer recurrent	PT
	18.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) FR (Ongoing) ES (Completed) GR (Completed) IT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2012-003214-13

Sponsor Protocol Number: I4X-MC-JFCL

Start Date*: 2013-07-19

Sponsor Name:Eli Lilly and Company

Full Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatme...

Medical condition: Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2016-003790-18

Sponsor Protocol Number: N16HYP

Start Date*: 2017-04-28

Sponsor Name:The Netherlands Cancer Institute

Full Title: Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally-advanced stage and / or inoperable non-small cell lung carcinoma

Medical condition: Locally advanced non-small cell lung carcinoma stage III or inoperable stage II

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025044	Lung cancer	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025053	Lung cancer non-small cell stage IIIA	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025054	Lung cancer non-small cell stage IIIB	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025051	Lung cancer non-small cell stage II	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025052	Lung cancer non-small cell stage III	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001252	Adenosquamous cell lung cancer stage IIIA	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001253	Adenosquamous cell lung cancer stage IIIB	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025060	Lung cancer stage II	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025061	Lung cancer stage III	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001255	Adenosquamous cell lung cancer stage unspecified	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001246	Adenosquamous cell lung cancer NOS	LLT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029518	Non-small cell lung cancer stage II	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Squamous cell lung carcinoma